Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Adenocarcinoma of the Pancreas|Adenocarcinoma of the Stomach|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Mucinous Cystadenocarcinoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Gastric Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific
Interventions: DRUG: veliparib|DRUG: capecitabine|DRUG: oxaliplatin|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)